Showing 8691-8700 of 9546 results for "".
- DefenAge Receives Two US Patents For Melasma and Hair Growthhttps://practicaldermatology.com/news/defenage-receives-two-us-patents-for-melasma-and-hair-growth/2461118/The US Patent and Trademark Office has granted two new patents to Defanage Skincare for the use of Defensin-molecules for topical treatment of hair loss in skin affected by alopecia and of the hyperpigmented lesions of melasma: &l
- Study: Laser Surgery Lawsuits Less Likely with Physician Operatorshttps://practicaldermatology.com/news/study-laser-surgery-lawsuits-less-likely-with-physician-operators/2461113/The majority of liability claims due to a cutaneous laser surgery device between 2012 and 2020 involved a non-physician operator, according to a new study in the March 2022 issue of Dermatologic Surgery. Researchers analyzed cases of liability claims due to a cutaneou
- Residents of Distinction Recognized at Maui Dermhttps://practicaldermatology.com/news/residents-of-distinction-honored-at-maui-derm/2461111/Sydney Liang, MD, a second-year resident at New York University, was awarded the Overall Grand Prize and was one of five dermatology residents recognized by DermMentors™ as part of the 11th Annual dermMentors™ Resident of Distinction Award™ for 2022.
- Vial Welcomes David Pariser, MD to its Boardhttps://practicaldermatology.com/news/vial-welcomes-david-pariser-md-to-its-board/2461105/David Pariser, MD has joined the Vial Scientific Advisory Board. The Senior Physician at Pariser Dermatology Specialists, Dr. Pariser will share the Vial CRO team and sponsors his knowledge and insights from more than 40 years as a practicing dermatologist. The
- Study: Use of DermTech’s Melanoma Test Can Cut Costshttps://practicaldermatology.com/news/study-use-of-dermtechs-melanoma-test-can-cut-costs/2461102/New research shows that DermTech’s Pigmented Lesion Assay can reduce costs for commercial health insurance plans when it’s incorporated into the current care pathway of assessing pigmented skin lesions or moles suspicious for melanoma The
- Positive Interim Data Seen with Sirnaomics Ltd’s STP705 in BCChttps://practicaldermatology.com/news/positive-interim-data-seen-with-sirnaomics-ltds-stp705-in-bcc/2461089/Interim data from a Phase 2 clinical trial of Sirnaomics Ltd’s STP705 shows a dose response with complete response, as well as improved or stable cosmetic result with no significant cutaneous skin reactions among patients with cutaneous basal cell carcinoma (BCC). The new data als
- Cyspera Launches New Three-Step System to Treat Hyperpigmentationhttps://practicaldermatology.com/news/cyspera-launches-new-three-step-system-to-treat-hyperpigmentation/2461083/Scientis is launching Cyspera Intensive System, a new three-product system designed to improve hyperpigmentation. Cysteamine inhibits several steps in the melanogenesis pathway while also working as antioxidant to protect against free radicals. The
- PCA SKIN Looks to Space for Next Breakthrough in Skin Healthhttps://practicaldermatology.com/news/pca-skin-looks-to-space-for-next-breakthrough-in-skin-health/2461077/PCA SKIN plans to send the first-ever private sector skin health experiment to the International Space Station (ISS). The experiment, sponsored by the ISS National Lab, will explore the effects of microgravity on skin-related biomarkers in an effort to guide future product innovat
- FDA Green-lights Casio’s DZ-D100 Dermocamera and the DZ-S50 Scopehttps://practicaldermatology.com/news/fda-green-lights-casios-dz-d100-dermocamera-and-the-dz-s50-scope/2461076/The U.S. Food and Drug Administration (FDA) has cleared Casio’s
- Study: Oral Dutasteride Outperforms Other Male Hair Loss Treatmentshttps://practicaldermatology.com/news/study-oral-dutasteride-outperforms-other-male-hair-loss-treatments/2461073/The top-ranking hair loss treatment for men is dutasteride (Avodart) capsules, at a dose of 0.5 milligrams a day, according to a new meta-analysis of 23 studies published online Feb. 2 in